Advertisement Fidelity
Home > Boards > US Listed > Biotechs > Ariad Pharmaceuticals, Inc. (ARIA)

A relevant excerpt from the patent application:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
iandy Member Profile
 
Followed By 7
Posts 2,564
Boards Moderated 1
Alias Born 06/09/10
160x600 placeholder
ARIAD to Webcast Conference Call on First Quarter 2014 Financial Results "Business Wire" - 4/16/2014 7:35:00 AM
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, ... "PR Newswire (US)" - 4/11/2014 8:00:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 4/9/2014 10:05:50 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/3/2014 4:32:48 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/3/2014 4:31:56 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/3/2014 4:31:08 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/3/2014 4:30:14 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/3/2014 4:29:28 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/3/2014 4:29:08 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/3/2014 4:28:20 PM
Clinical Study Initiations, Stock Price Updates, and Strategic Agreements - Analyst Notes on Ariad, Jazz, Intercept, Communit... "PR Newswire (US)" - 4/2/2014 8:00:00 AM
ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer "Business Wire" - 4/2/2014 7:35:00 AM
Technical Pointers on Top Gainers -- Research on ARIAD Pharma, Arotech, Restoration Hardware Holdings, and Sprouts Farmers Ma... "PR Newswire (US)" - 3/31/2014 12:52:00 PM
ARIAD startet Phase-2-Zulassungsstudie ALTA für AP26113 an Patienten mit nicht-kleinzelligem Lungenkrebs "Business Wire" - 3/25/2014 9:22:00 AM
ARIAD annonce le démarrage de l’essai pivot de Phase 2 « ALTA » portant sur l’AP26113 administré à des patients at... "Business Wire" - 3/25/2014 9:21:00 AM
ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer "Business Wire" - 3/24/2014 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/21/2014 5:31:07 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/21/2014 5:29:23 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/21/2014 5:28:56 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/21/2014 5:22:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/21/2014 5:21:21 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/21/2014 4:12:07 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/21/2014 4:11:12 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/21/2014 4:10:04 PM
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes... "PR Newswire (US)" - 3/12/2014 8:00:00 AM
iandy   Friday, 07/12/13 07:16:59 AM
Re: jaybe post# 32123
Post # of 48696 
A relevant excerpt from the patent application:

>There is no cure for PD. Current therapy relies heavily on replenishing dopamine by giving patients oral doses of a dopaminergic agent like the dopamine precursor levodopa (alone or in the combination carbidopa levodopa) or a dopamine agonist. Such therapy can provide relief, although with the increasing risk of serious side effects and often with diminishing therapeutic results, requiring increasing doses as treatment continues, and more serious side effects. There is a profound need for additional therapeutics for PD.

c-Abl is a major regulator of parkin function and phosphorylates parkin on tyrosine 143. This phosphorylation inhibits parkin's E3 ubiquitin ligase activity leading to

accumulation of AIMP2 and FBP1 and loss of parkin's cytoprotective function and cell death. One Abl inhibitor, STI-571 , has been found to maintain parkin in a catalytically active and neuroprotective state by preventing phosphorylation of parkin. As such, it is believed that inhibition of c-Abl presents a viable approach for the treatment of PD. o, et al., PNAS, 107(38), 16691 -16696 (2010). One challenge of using STI-571 to treat PD is that it has poor penetration of the blood-brain barrier as demonstrated in mice and humans. Thus, there is a need for Abl inhibitors that cross the blood-brain barrier for the treatment of PD.

Applicant's own WO 2007/075869, which is hereby incorporated herein by reference for all purposes, discloses certain compounds that inhibit inter alia Abl. One notable Abl inhibitor is ponatinib, which is currently the subject of a clinical trial to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation of Bcr-Abl (clinical trials.gov identifier NCT01207440). WO 2007/075869 does not explicitly mention using such Abl inhibitors for the treatment of PD.

SUMMARY

It has been unexpectedly discovered that certain Abl inhibitors cross the blood brain barrier and are useful in the regulation of parkin and accordingly for the treatment of PD.<



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist